Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.32
+0.58 (2.94%)
At close: Dec 5, 2025, 4:00 PM EST
20.90
+0.58 (2.85%)
After-hours: Dec 5, 2025, 7:09 PM EST
Syndax Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 111.3 | 23.68 | - | - | 139.71 | 1.52 | |
| Revenue Growth (YoY) | 595.65% | - | - | - | 9109.56% | - | |
| Cost of Revenue | 244.53 | 242.47 | 163.03 | 118.5 | - | - | |
| Gross Profit | -133.23 | -218.79 | -163.03 | -118.5 | 139.71 | 1.52 | |
| Selling, General & Admin | 167.44 | 120.88 | 66.92 | 33.26 | 25.24 | 22.51 | |
| Research & Development | 6.23 | - | - | - | 88.25 | 50.44 | |
| Operating Expenses | 173.67 | 120.88 | 66.92 | 33.26 | 113.49 | 72.94 | |
| Operating Income | -306.9 | -339.67 | -229.95 | -151.76 | 26.22 | -71.42 | |
| Interest Expense | -29 | -4.93 | -0.21 | -3.14 | -1.9 | -2.36 | |
| Interest & Investment Income | 25.51 | 26.09 | 21.16 | 5.87 | 0.4 | 0.84 | |
| Other Non Operating Income (Expenses) | -1.19 | -0.25 | -0.36 | -0.32 | 0.2 | -0.22 | |
| Pretax Income | -311.58 | -318.76 | -209.36 | -149.34 | 24.93 | -73.16 | |
| Net Income | -311.58 | -318.76 | -209.36 | -149.34 | 24.93 | -73.16 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 3.91 | |
| Net Income to Common | -311.58 | -318.76 | -209.36 | -149.34 | 24.93 | -77.06 | |
| Shares Outstanding (Basic) | 87 | 86 | 70 | 61 | 52 | 41 | |
| Shares Outstanding (Diluted) | 87 | 86 | 70 | 61 | 54 | 41 | |
| Shares Change (YoY) | 5.39% | 21.67% | 15.82% | 13.31% | 29.81% | 35.48% | |
| EPS (Basic) | -3.60 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 | |
| EPS (Diluted) | -3.60 | -3.72 | -2.98 | -2.46 | 0.46 | -1.87 | |
| Free Cash Flow | -311.01 | -274.9 | -160.6 | -133.68 | 29 | -71.26 | |
| Free Cash Flow Per Share | -3.59 | -3.21 | -2.28 | -2.20 | 0.54 | -1.73 | |
| Gross Margin | -119.70% | - | - | - | 100.00% | 100.00% | |
| Operating Margin | -275.73% | -1434.43% | - | - | 18.77% | -4708.17% | |
| Profit Margin | -279.93% | -1346.11% | - | - | 17.84% | -5080.03% | |
| Free Cash Flow Margin | -279.43% | -1160.91% | - | - | 20.76% | -4697.43% | |
| EBITDA | -306.9 | -339.66 | -229.94 | -151.72 | 26.26 | -71.33 | |
| EBITDA Margin | -275.73% | - | - | - | 18.80% | - | |
| D&A For EBITDA | 0 | 0.01 | 0.01 | 0.03 | 0.04 | 0.09 | |
| EBIT | -306.9 | -339.67 | -229.95 | -151.76 | 26.22 | -71.42 | |
| EBIT Margin | -275.73% | - | - | - | 18.77% | - | |
| Revenue as Reported | 111.3 | 23.68 | - | - | 139.71 | 1.52 | |
| Advertising Expenses | - | 7.3 | 6.1 | 1.5 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.